

**CLAIMS**

1. A method for determining clinical malignancy of FALS, characterized by isolating mutant SOD1 from a specimen taken from a FALS patient and evaluating the binding ability between said mutant  
5 SOD1 and TRAP $\delta$ .
2. A method for determining clinical malignancy of FALS, characterized by isolating mutant SOD1 from a specimen taken from a FALS patient and evaluating the binding ability between said mutant SOD1, and NEDL1 and Dvl1.
- 10 3. A method for determining clinical malignancy of FALS, characterized by isolating mutant SOD1 from a specimen taken from a FALS patient and evaluating the binding ability between said mutant SOD1 and NEDL1.
4. The use of NEDL1 or its substrate for determination of clinical  
15 malignancy of FALS.
5. The use of NEDL1 according to claim 4, characterized by using isolated mutant SOD1.
6. The use of NEDL1 according to claim 5, characterized in that said substrate is TRAP $\delta$  or Dvl1.
- 20 7. An inhibitor of interaction between mutant SOD1 and NEDL1 and/or its substrate.
8. An inhibitor according to claim 7, characterized in that said substrate is TRAP $\delta$  or Dvl1.
9. A method of screening for agents that are useful for treatment of  
25 FALS, characterized by determining whether or not a candidate drug is an inhibitor against interaction between mutant SOD1 and NEDL1

and/or its substrate in neurons.